



No: 01-NQ/ĐHĐCĐ-VDP

RESOLUTION
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025
Of VIDIPHA Central Pharmaceutical Joint Stock Company
Ho Chi Minh City, April 18th, 2025

-
- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17th, 2020.
 - Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26th, 2019.
 - Pursuant to the Charter of the Company.
 - Pursuant to the Minutes of the 2025 Annual General Meeting of Shareholders.

Today, April 18th, 2025, VIDIPHA Central Pharmaceutical Joint Stock Company held the 2025 Annual General Meeting of Shareholders. Attending the meeting were 23 shareholders owning and representing 19,723,518 voting shares, accounting for 89.31% of the charter capital. The General Meeting of Shareholders agreed to pass the following Resolution:

RESOLUTION

Article 1: Approve the figures in the financial statements for the fiscal year ending 31/12/2024, audited by AASC Auditing Firm Co., Ltd.

Voting rate: 100% agree. 0% disagree. 0% abstain.

Article 2: Approve the report of the Board of Directors.

Voting rate: 84% agree. 16% disagree. 0% abstain.

Article 3: Approve the report of the Board of Supervisors.

Voting rate: 100% agree. 0% disagree. 0% abstain.

Article 4: Approve the 2025 financial plan

- Total revenue: 1,050 billion VND (equal to 102% compared to 2024)
 - In which: Production revenue: 976 billion VND (increased by 104% compared to 2024)*
 - Other revenue: 74 billion VND (equal to 80% compared to 2024)*
- Total profit before tax : 92 billion VND (equal to 102% compared to 2024).
- Total salary fund : 100 billion VND.
- Dividend Percentage : From 25%/Charter Capital
- Investment in machinery and fixed assets: 20 billion VND.

- Bonus level for the Board of Management: 15% bonus on the profit exceeding the 2025 plan

Voting rate: 84% agree. 16% disagree. 0% abstain.

Article 5: Approve the remuneration for the Board of Directors and the Board of Supervisors in 2025 : equal to 4% of profit after tax in 2025 (including remuneration for members of the Board of Directors, the secretary of the Board of Directors, and the full-time Board of Supervisory, calculated as expenses, and for non-full-time members, deducted from profit after tax)

Voting rate: 100% agree. 0% disagree. 0% abstain.

Article 6: Approve the authorization of the Board of Directors to select one of the following four audit firms to audit the year 2025:

1/ AASC (Vietnam) Auditing Firm Company Limited.

2/ Ernst & Young Vietnam Limited.

3/ RSM Vietnam Auditing and Consulting Company Limited.

4/ Deloitte Vietnam Audit Company Limited.

Selection Criteria: The four aforementioned audit firms have been approved by the SSC to audit issuing organizations, listed organizations, and securities trading organizations in 2025.

Voting rate: 100% agree. 0% disagree. 0% abstain.

Article 7: Approve the General Director's Report on 2024 production and business results and 2024 profit distribution plan.

- | | |
|--|--|
| - Total revenue | : 1,031.46 billion VND. |
| - Total profit before tax | : 90.35 billion VND. |
| - Corporate income tax | : 18.53 billion VND. |
| - Total profit after tax | : 71.82 billion VND. |
| - Dividend payment 25%/Charter capital | : 55.21 billion VND. (Equals 76.87% of profit after tax) |
| - Allocation to company fund | : 16.61 billion VND. (Equals 23.13% of profit after tax) |
- In which:*
- | | |
|-------------------------------|--|
| + Development investment fund | : 10.87 billion VND. (Equals 15.13% of profit after tax) |
| + Bonus and welfare fund | : 5.75 billion VND. (Equals 8% of profit after tax) |

Voting rate: 84% agree. 16% disagree. 0% abstain.

Article 8: Approve the amendment of VIDIPHA's Charter according to Proposal 05/TTr-HĐQT, dated April 18th, 2025.

Voting rate: 81,26% agree. 18,74% disagree. 0% abstain.

Article 9: Approval of the preparation of a pre-feasibility investment project for a production line meeting EU-GMP standards according to Submission 04/TTr-HĐQT, dated April 18th, 2025.

Voting rate: 84% agree. 0% disagree. 16% abstain.

Article 10: Approve the dismissal of a member of the Board of Directors for the term V (2021-2026)

The 2025 Annual General Meeting of Shareholders has agreed to dismiss Ms. Nguyen Ngoc Trang as a member of the Board of Directors.

Voting rate: 100% agree. 0% disagree. 0% abstain.

Article 11: Approval of the candidate list and the number of members to be elected to the Board of Directors for the term V (2021-2026)

The 2025 Annual General Meeting of Shareholders has agreed to elect one additional member to the Board of Directors for the term V (2021 – 2026) according to the candidate list as follows:

No.	Full name	Year of birth	Professional Qualification
01	Kieu Thi Minh Hong	1979	Master's degree in Economics

Voting rate: 100% agree. 0% disagree. 0% abstain.

Article 12: Approval of the results of the election for additional members to the Board of Directors for the term V (2021 – 2026) as follows:

No.	Full name	Number of votes	Percentage
01	Kieu Thi Minh Hong	19,723,518	100%

Article 13: Implementation clause:

All shareholders, members of the Board of Directors, Board of Supervisors, Board of Management, and professional departments of the Company are responsible for implementing this Resolution.

This Resolution was read and approved before the Annual General Meeting of Shareholders on April 18th, 2025 with a voting rate of 100% agree, 0% disagree, 0% abstain.

**ON BEHALF OF THE
GENERAL MEETING OF SHAREHOLDERS
Chairperson of the Meeting – Chairman of the Board**



Kiên Hiền

**MINUTES OF THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
OF VIDIPHA CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY**

(April 18, 2025)

- Organization Name: Vidipha Central Pharmaceutical Joint Stock Company
- Head Office: 184/2 Le Van Sy, Ward 10, Phu Nhuan District, Ho Chi Minh City.
- Phone: (84-28) 38440 106 – 38443 869
- Fax: (84-28) 38440 446
- Email: ketoan@vidipha.com.vn
- Website: www.vidipha.com.vn

Today, April 18, 2025, at the Vidipha Central Pharmaceutical Joint Stock Company Hall, address 184/2 Le Van Sy - Ward 10 - Phu Nhuan District - Ho Chi Minh City.

The 2025 Annual General Meeting of Shareholders includes the following contents:

1. 14:00 - 14:20: Welcoming delegates and guests.
2. 14:20: Opening the meeting, declaring the reason, introducing delegates.
3. 14:30: The Board of Supervisors announces the results of the delegate eligibility check and declares the eligibility to hold the 2025 Annual General Meeting of Shareholders.
 - Total number of shareholders convened according to the list finalized on March 20, 2025: 625 shareholders owning 22,083,392 shares with voting rights.
 - Total number of shareholders attending the opening ceremony : 23 shareholders, owning: 19,723,518 shares, accounting for: 89.31 % of shares with voting rights. (attached list)
 - Approval of the Working Regulations at the General Meeting.
4. 14:35: The Organizing Committee introduces the members of the Presidium, the Secretary of the Delegation and the Ballot Counting Committee to their working positions:

- **The Presidium:**

1. Mr. Kieu Huu: Chairman of the Board of Directors of Vidipha Central Pharmaceutical Joint Stock Company

2. Mr. Hoang The Bac: Member of the Board of Directors, Deputy General Director and Chief Financial Officer of Vidipha Central Pharmaceutical Joint Stock Company.

- **Secretariat:**

1. Ms. Le Thi Thanh Thao

2. Mr. Nguyen Thanh Tung

- **Vote Counting Committee:**

1. Mr. Nghiem Minh Tuan

2. Mr. Huynh Vo Thuat

3. Mr. Truong Viet Thanh

5. 14:40: The Presidium announces the convening of the General Meeting of Shareholders, the conditions and procedures for holding the General Meeting of Shareholders in accordance with the provisions of the Enterprise Law and the Company's Charter. Total number of shareholders attending the opening ceremony : 23 shareholders, owning: 19,723,518 shares, accounting for: 89.31 % of shares with voting rights, eligible to hold the General Meeting of Shareholders. Presidium Introduces and approves the Agenda of the General Meeting:

- Statement of reasons.
- Report on checking shareholder qualifications - Approval of the Working Regulations at the General Meeting - Introduction and voting of the Presidium - Secretariat - Vote counting committee.
- Report of the General Director
- Report on the expected Profit Distribution and the Board of Directors' remuneration 2024.
- Report of the Board of Directors
- Report of the Supervisory Board
- Present the contents of the Proposals and amendments to the charter.
- Report on the list of candidates and the number of additional members of the Board of Directors for the V term (2021-2026)
- Present the election and candidacy regulations
- Voting instructions
- Discuss and vote to approve the contents of the Proposal and vote to elect additional members of the Board of Directors for the V term (2021-2026)
- Break
- Announce the results of the vote counting to approve the contents of the Proposal.
- Announce the results of the vote counting to elect additional members of the Board of Directors for the V term (2021-2026).
- Approve the Resolution of the 2025 Shareholders' Meeting
- Closing.

6. 14:45: Report of the General Director:

- Business performance results in 2024 and plan for 2025.
- Quick report on implementation of the first quarter of 2025.
- Project investment plan (GMP-EU).
- Project profit distribution plan for 2024
- Remuneration of the Board of Directors and the Supervisory Board in 2024
- Profit distribution plan for 2024 as follows: (Read the Profit Distribution Table 2024)
- Report on remuneration of the Board of Directors and the Supervisory Board in 2024 as follows:

Based on the remuneration level of the Board of Directors and the Supervisory Board in 2024 approved in the Resolution of the 2024 Annual General Meeting of Shareholders on April 13, 2024, it is 4% / profit after tax, equivalent to VND 2.87 billion. In 2024, actual expenditure:

The remuneration of the Board of Directors, the Supervisory Board and the Secretary of the Board of Directors is VND 2,016 billion, equivalent to 70.17% of the total remuneration allowed to be spent in 2024 and accounting for 2.81% of the 2024 profit after tax, the remaining amount will be refunded to the 2024 profit.

7. 14:55: Report of the Board of Directors:

- Report on the activities of the Board of Directors in 2024.
- Orientation of tasks in 2025

8. 15:20: Report of the Supervisory Board.

9. 15:30: The General Meeting discusses and votes to approve the contents of the reports:

- Approval of the figures in the financial statements ending the fiscal year on December 31, 2024 audited by AASC Auditing Firm Company Limited.
- Approval of the report of the Board of Directors.
- Approval of the report of the Supervisory Board.
- Approval of the 2025 financial plan
- Approval of the remuneration of the Board of Directors and the Board of Supervisors in 2025.
- Approval of the authorization for the Board of Directors to select the following Auditing Company to audit in 2025.
- Approval of the General Director's Report on the 2024 Business Performance Results and the 2024 Profit Distribution Plan.
- Approval of the amendment of the Charter of VIIDPHA Company according to Submission 05/TTr-HĐQT, dated April 18, 2025.
- Approval of the preparation of a pre-feasibility investment project for a production line meeting EU-GMP standards.
- Approval of the dismissal of members of the Board of Directors for the 5th term (2021-2026).
- Approval of the list of candidates and the number of additional members of the Board of Directors for the 5th term (2021-2026).

10. 15:40: Opinions of Vietnam Pharmaceutical Joint Stock Corporation at the 2025 General Meeting of Shareholders of Vidipha Central Pharmaceutical Joint Stock Company

- Agree on the contents of the 2024 report of the Board of Directors and the Board of General Directors, the 2024 profit distribution plan. Particularly for the 2025 Business Production Plan : Request that Vidipha Company considers developing a target for revenue and/or profit after tax in 2025 to grow by at least 8% compared to 2024, in accordance with the Government's direction in Resolution No. 25/NQ-CP dated February 5, 2025 on setting the overall growth target of the whole country in 2025 to reach 8% or more, creating a solid foundation to achieve a double-digit growth rate in the period between 2026 and 2030.
- Proposal to approve the amendment to the Charter of Vidipha Central Pharmaceutical Joint Stock Company : Request that Vidipha Central Pharmaceutical Joint Stock Company: (i) Develop a roadmap to increase the foreign ownership ratio appropriately, evaluate the effectiveness of cooperation in case Vidipha increases the foreign ownership ratio to a higher level; (ii) Develop criteria for selecting foreign investors to ensure the sustainable development of the Company.

11. 15:45: Dissemination of the Regulations on Election and Candidacy for the Board of Directors for Term V (2021-2026)

12. 15:50: Approval of the Regulations on Election and Candidacy for the Board of Directors for Term V (2021-2026) and Voting Method.

No.	Full name	Year of Birth	Professional Qualification
01	Kieu Thi Minh Hong	1979	Master's degree in Economics

13. 16:00: Instructions on voting to approve the contents of the submissions and elect additional members of the Board of Directors for Term V (2021-2026).

14. 16:05 Break, vote counting.

15. 16:20 Announcement of voting results to approve the contents of the submissions.

No.	Full name	Number of votes	Percentage
01	Kieu Thi Minh Hong	19,723,518	100%

16. 16:25 New members of the Board of Directors for term V (2021-2026) introduced to the General Meeting of Shareholders.

17. 16:30 Approval of the Resolution of the 2025 Annual General Meeting of Shareholders.

18. 16:40 Declare the closing of the General Meeting and vote to approve the Resolution of the 2025 Annual General Meeting of Shareholders.



KIEU HUU

RESIDIUM

HOANG THE BAC

SECRETARIAT

LE THI THANH THAO

NGUYEN THANH TUNG



VIDIPHA

Ho Chi Minh City, April 18th, 2025

No. 01/VDP-PPLN2024

DRAFT

PROFIT DISTRIBUTION PLAN FOR 2024

Following the 2024 audit results from AASC Auditing Company, the Board of Directors of VIDIPHA Central Pharmaceutical Joint Stock Company convened to assess production and business activities and propose the 2024 profit distribution plan for the General Meeting of Shareholders' approval, including the following:

I/ Revenue - Expenses - Profit:

Unit: VND

1. Total Revenue	1,031,675,964,346
2. Total Expenses	941,323,156,648
3. Total Profit Before Tax	90,352,807,698

II/ Profit Distribution

1. Corporate Income Tax Payable	18,529,589,799
2. Profit After Tax	71,823,217,899
3. Retained Earnings	
4. Profit for Dividend Payment and Fund Allocation	71,823,217,899
5. Dividend Payment (25%/Par Value) - (Equal to 76.87% of Profit After Tax)	55,208,480,000
6. Company Fund Allocation:	16,614,737,899
- Development Investment Fund - (Equal to 15.13% of Profit After Tax)	10,868,880,467
- Reward Fund - (Equal to 4% of Profit After Tax)	2,872,928,716
- Welfare Fund - (Equal to 4% of Profit After Tax)	2,872,928,716

III/ Share Capital Value After Profit Distribution:

1. Total Share Capital Value After Profit Distribution	681,434,669,105
Including:	
- Owner's Equity	220,833,920,000
- Share Premium	179,852,119,980
- Development Investment Fund	280,748,629,125
2. Book Value per Share	30,857
3. Value Added per Share Compared to Par Value	20,857

On behalf of the Board of Directors
CHAIRMAN

Pharmacist Kieu Huu

Ho Chi Minh City, April 18th, 2025

PROPOSAL TO THE SHAREHOLDERS' MEETING

Regarding: Approval of the contents of the 2025 Annual General Meeting of Shareholders

To: SHAREHOLDERS' MEETING

VIDIPHA CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17th, 2020.
- Pursuant to the Securities Law No. 54/2019/QH14 dated November 26th, 2019.
- Pursuant to the Charter of Organization and Operation of the Company.
- Pursuant to the audited financial statements for 2024.
- Based on the operating status of Vidipha Central Pharmaceutical Joint Stock Company.

The Board of Directors of Vidipha Central Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders for approval the following contents:

- 1- Approve the figures in the financial statements for the fiscal year ending December 31st, 2024, audited by AASC AUDITING FIRM Co., Ltd.**
- 2- Approve the report of the Board of Directors.**
- 3- Approve the report of the Board of Supervisors.**
- 4- Approve the remuneration for the Board of Directors and Board of Supervisors for 2025: equal to 4% of the profit after tax in 2025.** (including remuneration for members of the Board of Directors, the secretary of the Board of Directors, and fulltime members of the Supervisory Board, calculated as expenses, and part-time members deducted from profit after tax)
- 5- Approve the General Director's report on the business performance results of 2024 and the profit distribution plan for 2024.**

- Total revenue	: 1,031.46 billion VND.
- Total profit before tax	: 90.35 billion VND.
- Corporate income tax	: 18.53 billion VND.
- Total profit after tax	: 71.82 billion VND.
- Dividend payment 25%/Charter capital:	55.21 billion VND. (Equal to 76.87% of profit after tax)
- Allocation to the Company's fund	: 16.61 billion VND. (Equal to 23.13% of profit after tax)
<i>In which :</i>	
+ Development investment fund	: 10.87 billion VND. (Equal to 15.13% of profit after tax)
+ Reward and welfare fund	: 5.75 billion VND. (Equal to 8% of profit after tax)

Respectfully request the General Meeting of Shareholders to consider and approve.

Sincerely./.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

Ho Chi Minh City, April , 2025

PROPOSAL

Regarding: Selection of Independent Audit Firm for 2025

To: THE ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025

*- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17th, 2020;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26th, 2019;
- Pursuant to the Charter of Organization and Operation of Vidipha Central
Pharmaceutical Joint Stock Company.*

The Board of Supervisors of Vidipha Central Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders 2025 for approval the selection of an independent audit firm for 2025 as follows:

I. Approval of the list of 04 independent audit firms to review the semi-annual financial statements and audit the 2025 financial statements of the Company, including:

- 1/ AASC (Vietnam) Auditing Firm Company Limited
- 2/ Ernst & Young Vietnam Limited
- 3/ RSM Vietnam Auditing and Consulting Company Limited
- 4/ Deloitte Vietnam Audit Company Limited

Selection criteria: The above four audit firms have been approved by the State Securities Commission to audit public interest entities in the securities sector in 2025.

II. Authorizing the Board of Directors to select one of the above audit firms to review the semi-annual financial statements and audit the 2025 financial statements of the Company in accordance with current regulations at a reasonable fee.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Sincerely./.

Recipients:

- As above;
- BOD;
- File: Company Secretary, BOS.

**ON BEHALF OF THE BOARD OF
SUPERVISORS
HEAD OF THE BOARD**

Doan Thi Ngoc Boi

Ho Chi Minh City, April 18th, 2025

PROPOSAL TO THE SHAREHOLDERS' MEETING

Regarding: Approval of the 2025 Financial Plan

To: SHAREHOLDERS' MEETING

VIDIPHA CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY

- *Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17th, 2020.*
- *Pursuant to the Securities Law No. 54/2019/QH14 dated November 26th, 2019.*
- *Pursuant to the Company's Charter.*
- *Based on the audited financial statements of 2024.*
- *Based on the production and business activities of Vidipha Central Pharmaceutical Joint Stock Company.*

The Board of Directors of Vidipha Central Pharmaceutical Joint Stock Company submits to the Shareholders' Meeting for approval the financial plan for 2025, specifically as follows:

- Total revenue: 1,050 billion VND (*equal to 102% compared to 2024*)
 - In which : Production revenue: 976 billion VND (increased by 99% compared to 2024)*
 - Other revenue: 74 billion VND (equal to 80% compared to 2024)*
- Total profit before tax : 92 billion VND (*equal to 100% compared to 2024*).
- Total salary fund : 100 billion VND.
- Percentage of dividend : From 25%/Charter Capital
- Investment in machinery and fixed assets : 20 billion VND.
- Bonus level for the Board of Directors : Bonus of 15% on the profit exceeding the 2025 plan

Respectfully submitted to the Shareholders' Meeting for consideration and approval.

Sincerely./.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

KIEU HUU

Ho Chi Minh City, April 18th, 2025

PROPOSAL TO THE GENERAL MEETING OF SHAREHOLDERS

Regarding: Approval of investment policy for EU-GMP standard production line

To: GENERAL MEETING OF SHAREHOLDERS

VIDIPHA CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY

- *Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17th, 2020.*
- *Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26th, 2019.*
- *Pursuant to the Charter of Organization and Operation of the Company.*
- *Pursuant to Resolution No. 42-NQ/HĐQT-VDP of the Board of Directors, dated January 10th, 2025.*
- *Based on the production and business situation of Vidipha Central Pharmaceutical Joint Stock Company.*

The Board of Directors of Vidipha Central Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders for approval of the investment policy to build a Cephalosporin powder injection production line meeting EU-GMP standards, specifically as follows:

- **On products and market demand for the products:** The demand for Cephalosporin/Powder Injection/Group 1 & 2 products is currently over 30 million products/year, exceeding the capacity of existing EU/GMP powder injection plants. The emergence and rapid growth of the Cephalosporin group with Avibactam ensures good demand.

VDP is currently stably producing 5-7 million products/year of two types, Cefotaxime and Ceftazidim, and has previously produced two other types, Cefuroxim and Ceftriaxon.

- **On capital and investment scale:** The total estimated investment is 10 million USD, which is entirely within VDP's capacity for accumulation, borrowing, and repayment. The investment scale and procedures for appraisal and licensing will be shortened from the standard multi-year duration as it can be integrated into the currently operating WHO/GMP factory without changing the construction site.

- **On operational capacity:** Fundamentally easier and more stringent than VDP's 15 years of experience operating this powder injection line.

- **Regarding product development and registration:** It has begun and the licensing time can be shortened.

- **On the development and registration for circulation of products:** Parallel between investment and training, between EU/GMP training and GMP/WHO operation, along with inheriting all existing capital from 15 years of operating a similar line/same location/same product group.

Investing in the construction of a Cephalosporin powder injection production line that meets EU-GMP standards will enhance VIDIPHA's competitiveness, meet domestic demand, and target exports, thereby opening up new development directions for the company, contributing to boosting revenue and profits in the coming years.

To ensure feasibility, effectiveness, and optimization of investment resources, we respectfully request the General Meeting of Shareholders to approve the following contents:

Approve the assignment of the Board of Directors to hire a consulting unit to develop an investment project for the construction of a Cephalosporin powder injection production line meeting EU-GMP standards at the VIDIPHA factory (Binh Duong) for review by the Board of Directors before submission to the General Meeting of Shareholders for approval.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Sincerely./.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

KIEU HUU

PROPOSAL TO THE GENERAL MEETING OF SHAREHOLDERS
Regarding: Approval of amendments to the Charter of VIDIPHA Central Pharmaceutical Joint Stock Company

**To: GENERAL MEETING OF SHAREHOLDERS
VIDIPHA CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY**

- *Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17th, 2020.*
- *Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26th, 2019.*
- *Pursuant to Decree No. 155/2020/ND-CP dated December 31st, 2020.*
- *Pursuant to the Company's Charter of Organization and Operation.*
- *Based on the production and business situation of Vidipha Central Pharmaceutical Joint Stock Company.*

The Board of Directors of Vidipha Central Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders for approval the following contents:

Currently, according to the Company's Charter, the maximum ownership ratio of foreign investors in VIDIPHA Central Pharmaceutical Joint Stock Company (VIDIPHA Company) is 35%. In the spirit of the draft amendment to Decree 155/2020/ND-CP, the provision in the Company's Charter on limiting the maximum foreign ownership ratio lower than the permitted foreign ownership ratio according to regulations on business line conditions is no longer applicable. Besides, based on the development orientation of VIDIPHA Company in the coming time, it is necessary to expand cooperation with foreign investors to receive new technologies, licensed production, export processing, and market expansion, thereby increasing sales and profits as well as the position of VIDIPHA Company in the future.

Therefore, to comply with current legal regulations and be consistent with the upcoming draft amendment, and to facilitate cooperation with foreign partners in the future, we respectfully submit to the General Meeting of Shareholders for approval the following contents:

1. Approve the amendment to remove the regulation on the maximum foreign ownership ratio in Clause 6, Article 6 of the Company's Charter.
2. Authorize the Board of Directors to notify the State Securities Commission of the adjustment of the maximum foreign ownership ratio in accordance with current legal regulations.

Sincerely./.

**ON BEHALF OF THE
BOARD OF DIRECTORS
CHAIRMAN**

Ho Chi Minh City, April2025

PROPOSOL TO THE SHAREHOLDERS' MEETING

Regarding: Approval of the dismissal of member of the Board of Director (2021 – 2026)

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated 17/ 6/2020.
- Pursuant to the Securities Law No. 54/2019/QH14 dated 26/11/2019.
- Pursuant to Decree No. 155/2020/ND-CP dated 31/12/2020.
- Pursuant to the Charter of Organization and Operation of the Company.
- Based on the resignation letter of the member of the Board of Directors.

The Board of Directors of Vidipha Central Pharmaceutical Joint Stock Company respectfully submits to the 2025 Annual General Meeting of Shareholders for approval the dismissal of a member of the Board of Directors as follows:

At the 2021 Annual General Meeting of Shareholders (24/04/2021) and the 2023 Annual General Meeting of Shareholders (15/04/2023), the General Meeting elected 07 members of the Board of Directors for term V (2021-2026) as follows:

- 1- Kieu Huu
- 2- Hoang Van Hoa
- 3- Pham Tuan Kiet
- 4- Tran Van Dat
- 5- Nguyen Ngoc Trang
- 6- Nguyen Tran Hieu
- 7- Hoang The Bac

Based on the resignation letter of Ms. Nguyen Ngoc Trang from the position of member of the Board of Directors, the Board of Directors respectfully submits to the General Meeting of Shareholders for approval the dismissal of Ms. Nguyen Ngoc Trang from the Board of Directors.

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Sincerely yours./.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

KIEU HUU

Ho Chi Minh City, April2025

PROPOSOL TO THE SHAREHOLDERS' MEETING

Regarding: Approval of the list of candidates and the number of supplementary members to be elected to the Board of Directors for the term V (2021-2026)

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated 17/ 6/2020.
- Pursuant to the Securities Law No. 54/2019/QH14 dated 26/11/2019.
- Pursuant to Decree No. 155/2020/ND-CP dated 31/12/2020.
- Pursuant to the Charter of Organization and Operation of the Company.
- Based on the resignation letter of the member of the Board of Directors.
- Based on the nomination and candidacy documents for the supplementary election of members to the Board of Directors for the term V (2021-2026).

The Board of Directors of Vidipha Central Pharmaceutical Joint Stock Company respectfully submits to the 2025 Annual General Meeting of Shareholders as follows:

1/ List of candidates and the number of supplementary members to be elected to the Board of Directors for the term V (2021-2026) include 1 candidate:

STT	Full Name	Year of Birth	Professional Qualifications
01	Kieu Thi Minh Hong	1979	Master's degree in Economics

(Attached: Resume of candidate)

2/ Number of Board of Directors members for the term V (2021 – 2026):

- According to the provisions in Clause 1, Article 154 of the 2020 Enterprise Law: "The Board of Directors must have from 03 to 11 members. The Company's Charter specifies the number of Board members."
- According to Clause 1, Article 26 of the Charter of VIDIPHA Pharmaceutical Joint Stock Company: "The number of Board of Directors members is 07 (seven) people."
- After one Board member resigned, the current number of Board members is 06. Therefore, the Board of Directors of VIDIPHA Pharmaceutical Joint Stock Company respectfully presents to the 2021 Annual General Meeting of Shareholders for approval of the election of **01 additional member** to the Board of Directors for the term V (2021 – 2026).

Respectfully submitted to the General Meeting of Shareholders for consideration and approval.

Sincerely yours./.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

KIEU HUU

**VIDIPHA CENTRAL PHARMACEUTICAL
JOINT STOCK COMPANY**
184/2 Le Van Sy – Ward 10 – Phu Nhuan
District

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness
.....,.....2025

SELF-NOMINATION LETTER FOR BOARD OF DIRECTORS MEMBER

**To: 2025 Annual General Meeting of Shareholders of VIDIPHA Central
Pharmaceutical Joint Stock Company**

My name is: KIEU THI MINH HONG.....

I currently own 0 shares, and have been nominated by shareholders owning 2.484.937 shares,
equivalent to 11,25% of the Company's charter capital.

Having met the conditions specified by current laws and the Company's Charter, I hereby
submit this letter to request my candidacy for election as a member of the Board of Directors for
Term V (2021 – 2026) at the 2025 Annual General Meeting of Shareholders.

Attached are the documents, includes:

- Nomination letter (if any)
- Notarized resume
- Notarized copies of: ID card, academic certificates, and professional qualifications.

If elected, I commit to strictly complying with the current laws and the Company's Charter.

Sincerely.

.....,2025
CANDIDATE
(Sign and full name)

KIEU THI MINH HONG

Note: The original self - nomination documents for candidates to the Board of Directors must be
submitted to the following address: Shareholders' Meeting Organizing Committee, VIDIPHA Central
Pharmaceutical Joint Stock Company, 184/2 Le Van Sy, Ward 10, Phu Nhuan District, Ho Chi Minh
City, before 4:00 PM on April 7, 2025. (Section 3, Article 274, Clause 1 of Decree 155/2020/ND-CP,
dated December 31, 2020).



No: 260325.011/BCTC.KT2

INDEPENDENT AUDITOR'S REPORT

To: Shareholders, The Board of Director and The Board of Management
Vidipha Central Pharmaceutical Joint Stock Company

We have audited the accompanying Financial Statements of Vidipha Central Pharmaceutical Joint Stock Company prepared on 26 March 2025 from page 06 to page 37, including: Statement Of Financial Position as at 31 December 2024, Statement Of Income, Statement Of Cash Flows and Notes to The Financial Statements for the fiscal year ended 31 December 2024.

The Board of Management' responsibility

The Board of Management is responsible for the preparation and presentation of Financial Statements that give a true and fair view in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of Financial Statements and for such internal control as directors determines is necessary to enable the preparation and presentation of Financial Statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these Financial Statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with standards and ethical requirements; plan and perform the audit to obtain reasonable assurance about whether the Separate Financial Statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and presentation of Financial Statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Board of Management, as well as evaluating the overall presentation of the Financial Statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Auditor's opinion

In our opinion, the Financial Statements give a true and fair view, in all material respects, of the financial Position of Vldipha Central Pharmaceutical Joint Stock Company as at 31 December 2024, its operating results and its cash flows for the year then ended in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to preparation and presentation of Financial Statements.

AASC Auditing Firm Company Limited



Vu Xuan Bien
Deputy General Director
Certificate of registration to audit practice
No: 0743-2023-002-1

Nguyen Trung Kien
Auditor
Certificate of registration to audit practice
No: 5136-2025-002-1

Hanoi, 26 March 2025

VIDIPHA CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY
CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR 2024
As of December 31, 2024
Audited by
AASC Auditing Firm Company Limited

A. BALANCE SHEET

Unit: VND

NO.	INDICATORS	31/12/2024	01/01/2024
I	CURRENT ASSETS	922,221,272,793	875,016,373,267
1	Cash and cash equivalents	123,830,952,476	213,987,603,712
2	Short-term investments	192,789,930,016	119,000,000,000
3	Short-term receivables	256,058,796,626	238,612,274,837
4	Inventories	346,483,278,908	296,735,523,987
5	Other current assets	3,058,314,767	6,680,970,731
II	NON-CURRENT ASSETS	203,609,067,081	218,429,005,997
1	Long-term receivables	417,433,359	1,037,530,568
2	Fixed assets	194,716,269,641	210,977,229,959
	Tangible fixed assets	155,537,345,506	172,051,409,984
	Intangible fixed assets	39,178,924,135	38,925,819,975
3	Long-term assets in progress	108,975,340	203,753,427
4	Long-term investments		5,000,000,000
5	Other long-term assets	8,366,388,741	1,210,492,043
	TOTAL ASSETS	1,125,830,339,874	1,093,445,379,264
III	LIABILITIES	374,058,044,861	361,463,196,271
1	Current liabilities	374,058,044,861	361,463,196,271
2	Non - current liabilities		
IV	OWNER'S EQUITY	751,771,295,013	731,982,182,993
	Owner's equity	751,771,295,013	731,982,182,993
	Contributed capital	220,833,920,000	184,029,040,000
	Share premium	179,852,119,980	216,656,999,980
	Other capital		
	Treasury shares (*)	-	-
	Investment and development fund	269,879,748,658	242,085,672,537
	Enterprise reorganization assistance fund	81,205,506,375	89,210,470,476
	TOTAL CAPITAL	1,125,829,339,874	1,093,445,379,264

VIDIPHA CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY

B. INCOME STATEMENT

Unit: VND

INDICATOR	Year 2024	Year 2023
1. Revenue from sales of goods and rendering of services	980,977,289,012	1,075,906,262,997
2. Revenue deductions	46,490,466,442	56,589,577,170
3. Net revenue from sales of goods and rendering of services	934,486,822,570	1,019,316,685,827
4. Cost of goods sold and services rendered	704,747,586,470	748,736,585,717
5. Gross profit from sales of goods and rendering of services	229,739,236,100	270,580,100,110
6. Financial income	20,266,053,722	19,581,958,769
7. Financial expense	17,895,020,830	27,561,779,900
- In which: Interest expense	14,848,776,129	27,558,626,120
8. Selling expense	81,515,451,162	120,306,598,713
9. General and administrative expense	66,358,009,228	51,113,725,170
10. Net profit from operating activities	84,236,808,602	91,179,955,096
11. Other income	76,703,838,947	74,423,952,969
12. Other expense	70,587,839,854	65,035,322,378
13. Other profit	6,115,999,093	9,388,630,591
14. Total net profit before tax	90,352,807,695	100,568,585,687
15. Current corporate income tax expense	18,529,589,799	20,349,742,077
16. Deferred corporate income tax expense		
17. Profit after corporate income tax	71,823,217,896	80,218,843,610
18. Basic earnings per share	3,252	3,886

C. KEY FINANCIAL INDICATORS

INDICATORS	Year 2024	Year 2023
Asset Structure		
1. Short-term Assets/Total Assets (%)	81.91%	80.02%
Long-term Assets/Total Assets (%)	18.09%	19.98%
Capital Structure		
2. Liabilities/Total Capital (%)	33.23%	33.06%
Owner's Equity/Total Capital (%)	66.77%	66.94%
Liquidity Ratios		
3. Quick Ratio (times)	1.54	1.60
Current Ratio (times)	2.47	2.42
Profitability Ratios (%)		
4. Net Profit after Tax/Total Assets (%)	6.38%	7.34%
Net Profit after Tax/Net Revenue (%)	7.69%	7.87%
Net Profit after Tax/Owner's Equity (%)	9.55%	10.96%